Myeloid Therapeutics Announces SITC 2024 Oral Presentation on MT-303, the First in vivo GPC3 Targeting mRNA CAR in Human Studies for Advanced Hepatocellular Carcinoma (HCC)
View Press Release.
Eureka Therapeutics Treats First Patient with GPC3 Targeting ARTEMIS® T Cells (ECT204) for Advanced Liver Cancer
View Press Release.
NIH Clinical study - CAR-T Cell Treatment for Patients with Glypican-3 (GPC3) Positive HCC
More information on NIH Website.
RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial
View abstract in PubMed.
High Glypican-3 expression Characterizes a Biologically Distinct subset of ovarian clear cell carcinomas in Canadian patients: An Opportunity for targeted Therapy.
View abstract on PubMed.
Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma.
View abstract on PubMed.
I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma
View article on PubMed.
Sky Vegas review bettingy.com/sky-vegas-casino read at bettingy.com